马栗种子提取物治疗ⅢB型前列腺炎疗效观察

Curative effect of the extract of horse chestnut seeds for treatment of ⅢB prostatitis

目的探讨马栗种子提取物治疗ⅢB型前列腺炎的临床效果。方法选取2015年8月至2016年6月新乡医学院第一附属医院收治的ⅢB型前列腺炎患者81例,按治疗方法将患者分为观察组(n=40)和对照组(n=41)。对照组患者给予盐酸坦索罗辛缓释胶囊和前列舒通胶囊治疗,观察组患者给予马栗种子提取物、盐酸坦索罗辛缓释胶囊和前列舒通胶囊治疗。观察2组患者用药4周后的临床治疗效果,并观察2组患者治疗前后前列腺炎症状指数(NIH-CPSI)评分及前列腺液(EPS)中白细胞计数(WBC)、白细胞介素-8(IL-8)及肿瘤坏死因子-α(TNF-α)水平的变化。结果治疗过程中对照组脱落4例(2例中断服药,2例未按时复诊),观察组脱落6例(3例拒绝按治疗方案服药,1例中断服药,2例未按时复诊),最终对照组纳入病例37例,观察组纳入病例34例。用药4周后,对照组37例患者中,临床治愈2例(5.40%),显效4例(10.81%),有效19例(51.35%),无效12例(32.43%);观察组34例患者中,临床治愈3例(8.82%),显效14例(41.18%),有效14例(41.18%),无效3例(8.82%);观察组患者的临床疗效显著优于对照组(P<0.05)。2组患者均未发生不良反应。2组患者治疗前NIH-CPSI评分、EPS-WBC及EPS中的IL-8、TNF-α水平比较差异均无统计学意义(P>0.05);2组患者治疗后的EPS-WBC与治疗前比较差异均无统计学意义(P>0.05),NIHCPSI评分及EPS中的IL-8、TNF-α水平均显著低于治疗前(P<0.05);治疗后,观察组患者的EPS-WBC与对照组比较差异无统计学意义(P>0.05),NIH-CPSI评分及EPS中的IL-8、TNF-α水平与对照组比较显著降低(P<0.05)。结论马栗种子提取物治疗ⅢB型前列腺炎可显著降低EPS中炎性因子水平,具有良好的临床效果,且不良反应少,可以作为此类患者的辅助用药。

Objective To investigate the curative effect of the extract of horse chestnut seeds for treatment of m B prostatitis. Methods A total of 81 patients with ⅢB prostatitis were selected from August 2015 and June 2016 in the First Affiliated Hospital of Xinxiang Medical University. The patients were divided into control group（ n = 41 ）and observation group（ n = 40） according to the treatment method. The patients in the control group were treated with tamsulosin hydrochloride sustained release capsules and Qianlie Shutong capsules, while the patients in the observation group were treated with extract of horse chestnut seeds, tamsulosin hydrochloride sustained release capsules and Qianlie Shutong capsules. The treatment effect was ob- served after treatment for 4 weeks. The National Institutes of Heahh-ehronic prostatitis symptom index （NIH-CPSI） score and the levels of interleukin-8 （ IL-8 ）, tumor necrosis factor-α （TNF-α） in liquor prostaticus were detected before and after treatment in the two groups. Results During the course of treatment ,4 cases （2 cases discontinued medication ,2 cases did not return visit on time）in the control group and 6 cases （3 cases refused to take medication according to the treatment plan, 1 case discontinued medication, and the other 2 cases failed to return visit on time）in the observation group withdrew. Thirty-seven cases in control group and thirty-four cases in observation group were enrolled finally. Four weeks after treatment, the resuhs of the 37 cases in the control group were clinical cure in 2 cases（5.40% ） ,markedly effective in 4 cases（ 10. 81% ） ,effective in 19 cases（51.35% ）and ineffective in 12 cases （32.43%） ;the resuhs of the 34 cases in the observation group were clinical cure in 3 cases （8.82%） , markedly effective in 14 cases （41.18%） , effective in 14 cases （41.18%）and ineffective in 3 cases trol group（ P 〈 0.05 ）. The heart rate（HR） of patients in the observation at T2 - T8 was significantly lower than that at T, （ P 〈 O. 05 ） ;there was no statistic difference in the systolic blood pressure （SBP）, diastolic blood pressure （DBP）of patients between T2 - Ts and T- in the observation group（ P 〉 0.05 ）. The SBP, DBP of patients in the control group at T2 - T6 were significantly lower than those at T1 （P 〈 O. 05） ;there was no statistic difference in the SBP,DBP between T7 ,Ts and T1 （P 〉0.05） ;there was no statistic difference in the HR between T2 - T8 and T1 （P 〉 0.05 ）. There was no statistic difference in the SBP, DBP and HR at T1 between the two groups（P 〉0.05） ;the SBP,DBP of patients at T2 - T6 in the observation group was significanhy higher than that in the control group （ P 〈 0.05 ） ; there was no statistic difference in the SBP, DBP of patients at T7 , Ts between the two groups （P 〉 0.05 ） ;the HR of patients at T2-T8 in the observation group was significantly lower than that in the control group（P 〈 0.05）. Conclusion Dexmedetomidine pretreatment can reduce the serum level of S100β protein in patients who undergo craniotomy surgery. It has protection action on brain cell.